Based on our findings that chidamide combined with cytarabine inhibits the MYC-RRP9 pathway (Figs. 3 and 4) and that reduced RRP9 impairs ribosome biogenesis in AML (Fig. 6), we further examined the effects of this combination on ribosome biogenesis. This evidence concerns the gene MYC and acute myeloid leukemia.